WT1基因在白血病患者中的表达及临床意义
Expression of Wilms' Tumor Gene（WT1） in Leukemia Patients and Its Clinical Significance
-
摘要: ［摘要］目的 研究WT1基因在白血病患者中的表达及其临床意义．方法 运用RT-PCR方法检测 WT1基因在200例白血病患者中的表达．结果 急性髓细胞白血病（AML）和急性淋巴细胞白血病（ALL）WT1表达阳性率分别为79.2%（76/96）和57.1%（32/56）．慢性粒细胞白血病（CML）慢性期WT1表达均阴性，急变期57.1%（8/14）表达阳性．WT1阳性患者化疗缓解率低于阴性患者（分别为55.7%和85.4%，P＜0.05）．结论 WT1在白血病患者中高表达，可作为临床评估预后、检测微小残留病（MRD）的标志．Abstract: ［Abstract］Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication．Method Nest RT-PCR technique was applied to examine WT1 gene expression in 200 patients with leukemia．Results The WT1 mRNA positive rates in acute myeloid leukemia and lymphoblastic leukemia were 79.2%（76/96）and 57.1%（32/56）. In chronic myeloid leukemia，WT1 mRNA was undetectable in chronic phase; but was revealed in 8 of 14 patients at blast crisis（57.1%）. The rate of remission in the patients positive for WT1 was lower than in those negative for WT1（55.7% vs 85.4%，P＜0.005）．Conclusion The WT1 is highly expressed in the majority of the patients with leukemia and thus is involved in human leukemogenesis. WT1 may be a new prognostic factor and a panleukemia marker for the detection of MRD.
-
点击查看大图
计量
- 文章访问数: 1908
- HTML全文浏览量: 642
- PDF下载量: 410
- 被引次数: 0
下载:
